Collaboration integrates AJICAP™ technology with global manufacturing capabilities to streamline antibody-drug conjugate pipelines
TheraNym will set up a greenfield large-scale mammalian drug substance manufacturing facility
Veteran biopharma leader stressed that generic medicines must be viewed separately from biologics
This event will bring together global stakeholders to explore India’s growing capabilities in pharma and biopharma innovation, research, and manufacturing
The two-day conference and exhibition features discussions on policy frameworks, AI-led drug discovery, next-generation technologies, and global competitiveness
Nature Medicine study delivers strongest real-world evidence yet for India’s indigenous rotavirus vaccine under UIP
For the biopharma industry, the study strengthens the case for balancing immune-cell engagement with tolerability in antibody discovery platforms
The patent, titled “ALPHA-1062 for treating Traumatic Brain Injury,” strengthens Alpha Cognition’s existing portfolio supporting both ALPHA-1062 and ZUNVEYL
Biopharma companies face persistent hurdles in cell line development, including long timelines, low yields, and high failure rates for novel molecules
Interchangeable biosimilars to Prolia and Xgeva target osteoporosis and cancer-related bone complications in a $5 billion U.S. market
The drug meets all primary endpoints across 608 patients in Europe and India, strengthening the company's biosimilars pipeline
India’s first prospective study finds molecular testing improved diagnostic clarity in 50% of complex sarcoma cases
The JADE trial enrolled 164 U.S. patients who initially received three monthly doses of OLN324 or faricimab, followed by 12 weeks off treatment with retreatment allowed only if disease recurred
Key FDA decisions and pivotal late-stage obesity and breast cancer data could reshape competitive positioning
The move comes as China rapidly expands its capabilities in the pharmaceutical sector, particularly in licensing and drug development
Indomo’s ClearPen system combines a proprietary self-injection device and microneedle with a modernized triamcinolone acetonide formulation
To support this launch, ImmunityBio has established a wholly owned subsidiary in Saudi Arabia
A final tranche of €12 million will follow, contingent on positive pivotal study results, with the share price calculated according to an agreed formula
Achondroplasia is a genetic condition driven by FGFR3 that affects more than stature alone
Subscribe To Our Newsletter & Stay Updated
